Amoxicillin-clavulanic acid and ciprofloxacin-treated SPF mice as gnotobiotic model.
The experiment was carried out on 24 SPF BALB/c female mice and lasted for 15 days with a 5-day antibiotic (ATB) treatment and then 10 days without ATB treatment. The aim of our study was to acquire an animal model with reduced and controlled microflora and, at the same time, to ensure that the good health of these animals is maintained. Per oral administration of amoxicillin and clavulanate potassium in Amoksiklav (Sandoz, Slovenia) at a dose of 387.11 mg/kg body weight (0.2 ml of dilution per mouse) and subcutaneous administration of ciprofloxacin in Ciloxan (Alcon, Spain) at a dose of 18.87 mg/kg body weight (0.1 ml of dilution per mouse) were performed every 12 h during first 5 days of experiment. Five-day treatment with ATB led to a reduced survivability of microorganisms in faeces (28.33 ± 0.43 % on day 2) and caecum content (28.10 ± 1.56 %), where no cultivable microorganisms in faeces were present. Ten-day convalescence of decontaminated animals under gnotobiotic conditions prevented recovery of species diversity in mice gut microflora. This was reduced to two detectable cultivable species, namely Escherichia coli (GenBank KX086704) and Enterococcus sp. (GenBank KX086705) which were capable to restore its metabolic (CRL 2012) and morphological potential (Baratta et al. Histochem Cell Biol 131:713-726, 2009) within physiological range. Animals obtained under this procedure can be used in further studies. As a result, we created a mouse gnoto model with reduced and controlled microflora without alteration of the overall health status of the respective animals.
Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Košice, Košice, Slovakia. miro.popper@gmail.com.
Miroslav
M
Popper
Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Košice, Košice, Slovakia.
Soňa
S
Gancarčíková
Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Košice, Košice, Slovakia.
Marián
M
Maďar
Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Košice, Košice, Slovakia.
Dagmar
D
Mudroňová
Institute of Parasitology, Slovak Academy of Sciences, Košice, Slovakia.
Gabriela
G
Hrčková
Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Košice, Košice, Slovakia.
Radomíra
R
Nemcová
D019980:Amoxicillin-Potassium Clavulanate Combination / Q000008:administration & dosage*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002432:Cecum / Q000382:microbiology; D002939:Ciprofloxacin / Q000008:administration & dosage*; D005243:Feces / Q000382:microbiology; D005260:Female; D005856:Germ-Free Life; D008807:Mice, Inbred BALB C; D023421:Models, Animal; D013997:Time Factors; D065093:beta-Lactamase Inhibitors / Q000008:administration & dosage*
D000900:Anti-Bacterial Agents; D065093:beta-Lactamase Inhibitors; D002939:Ciprofloxacin; D019980:Amoxicillin-Potassium Clavulanate Combination
Amoxicillin-clavulanic acid; Ciprofloxacin; Gnotobiotic; Mice